Brainstorm Cell Net Income Over Time
| BCLI Stock | USD 0.54 0.04 6.90% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Brainstorm Cell Performance and Brainstorm Cell Correlation. Brainstorm | Build AI portfolio with Brainstorm Stock |
Is there potential for Biotechnology market expansion? Will Brainstorm introduce new products? Factors like these will boost the valuation of Brainstorm Cell. Projected growth potential of Brainstorm fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Brainstorm Cell's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Brainstorm Cell should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Brainstorm Cell's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Brainstorm Cell Ther and related stocks such as Neurosense Therapeutics, Matinas BioPharma, and Adial Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| MTNB | (116.1 K) | (116.1 K) | (116.1 K) | (3.7 M) | (10.2 M) | (9.1 M) | (7.6 M) | (15.5 M) | (14.1 M) | (17.4 M) | (22.4 M) | (23.3 M) | (21 M) | (22.9 M) | (24.3 M) | (21.8 M) | (22.9 M) |
| ADIL | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (420.2 K) | (1.1 M) | (11.6 M) | (8.6 M) | (10.9 M) | (19.4 M) | (12.7 M) | (7 M) | (13.2 M) | (11.9 M) | (12.5 M) |
| CDIO | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (620.4 K) | (4.7 M) | (8.4 M) | (8.4 M) | (7.5 M) | (7.2 M) |
| HCWB | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (5.8 M) | (12.9 M) | (14.9 M) | (25 M) | (30 M) | (27 M) | (25.7 M) |
| IBO | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (98.1 K) | (590.1 K) | (760.1 K) | (3.9 M) | (7.1 M) | (4.3 M) | (2.1 M) | (1.8 M) | (1.9 M) |
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.7 M) | (12.1 M) | (14.6 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| VYNE | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (14.1 M) | (29.1 M) | (51.4 M) | (70.5 M) | (255.6 M) | (73.3 M) | (23.2 M) | (28.5 M) | (39.8 M) | (35.9 M) | (37.6 M) |
| ADXN | (20.5 M) | (31.1 M) | (26.6 M) | (14.5 M) | (1.8 M) | (4.2 M) | (3.1 M) | (3.3 M) | (1.6 M) | (14.8 M) | (12.9 M) | (15.4 M) | (20.8 M) | (10.6 M) | 7.1 M | 8.1 M | 8.5 M |
| BCDA | 135.6 K | 9.7 M | 305 K | 19 K | 234 K | 322 K | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (7.9 M) | (7.2 M) | (6.8 M) |
Brainstorm Cell Ther and related stocks such as Neurosense Therapeutics, Matinas BioPharma, and Adial Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Brainstorm Cell Ther financial statement analysis. It represents the amount of money remaining after all of Brainstorm Cell Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Brainstorm Cell Therapeutics | BCLI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1325 Avenue of |
| Exchange | NASDAQ Exchange |
USD 0.54
Check out Brainstorm Cell Performance and Brainstorm Cell Correlation. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Brainstorm Cell technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.